PAX Therapeutics, Inc
PAX Therapeutics is a US-based biotechnology company developing a locally delivered AAV2-based gene therapy to improve healing of tendon and ligament injuries in humans and animals. The company has completed preclinical studies and GLP toxicology/dose-range work in support of an anticipated IND filing and is preparing early-phase clinical evaluation.
Industries
N/A
Nr. of Employees
small (1-50)
Products
PAX-001 (AAV2-based local gene therapy)
An AAV2 vector encoding a growth factor designed for local delivery to tendons and ligaments to stimulate vascularization and Type I collagen production and improve repair outcomes.
PAX-001 (AAV2-based local gene therapy)
An AAV2 vector encoding a growth factor designed for local delivery to tendons and ligaments to stimulate vascularization and Type I collagen production and improve repair outcomes.
Expertise Areas
- Gene therapy for musculoskeletal repair
- Preclinical tendon and ligament models
- IND-enabling study execution
- Early-phase clinical trial design (Phase 1/1b)
Key Technologies
- AAV2 vector-based gene delivery
- Local intratendinous/intraligamentous injection
- Ultrasound-guided percutaneous injection
- GLP toxicology and dose-range studies
News & Updates
Invited scientific updates presented at the Staten Serum Institute (Copenhagen) and Karolinska Institutet, and a presentation at the Swedish Virology Society meeting.
Company founder interviewed in an Innovator Q&A section.
Coverage noting the company as one of Ocean State Labs' inaugural tenants.
Award to fund preparation of GLP study documentation for an IND submission to the US FDA.
Company featured in a Rhode Island Bio profile of innovators.
Invited scientific updates presented at the Staten Serum Institute (Copenhagen) and Karolinska Institutet, and a presentation at the Swedish Virology Society meeting.
Company founder interviewed in an Innovator Q&A section.
Coverage noting the company as one of Ocean State Labs' inaugural tenants.
Award to fund preparation of GLP study documentation for an IND submission to the US FDA.
Company featured in a Rhode Island Bio profile of innovators.